{
    "clinical_study": {
        "@rank": "16828", 
        "acronym": "HM PHP CE Mark", 
        "arm_group": {
            "arm_group_label": "Percutaneous coronary intervention", 
            "arm_group_type": "Experimental", 
            "description": "Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention"
        }, 
        "brief_summary": {
            "textblock": "The HeartMate PHP is a catheter-based pump designed to provide partial left heart\n      circulatory support.  The study will assess the safety and performance of the HeartMate PHP\n      in supporting patients who are hemodynamically unstable, or at risk of being hemodynamically\n      unstable, while undergoing percutaneous coronary interventions (PCI), such as coronary stent\n      placement."
        }, 
        "brief_title": "HeartMate\u00ae PHP CE Mark Clinical Investigation Plan", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "High Risk Percutaneous Coronary Intervention", 
        "detailed_description": {
            "textblock": "The HeartMate PHP (percutaneous heart pump) is a catheter-based axial flow pump designed to\n      provide partial left ventricular circulatory support.  The primary objective of this\n      prospective, nonrandomized, multi-center, open-label trial is to assess the safety and\n      performance of the HeartMate PHP in supporting patients who are hemodynamically unstable, or\n      at risk of being hemodynamically unstable, while undergoing percutaneous coronary\n      interventions (PCI)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age.\n\n          -  Patient presents with a non-emergent need for complex PCI with:\n\n               1. an ejection fraction of \u226435% requiring hemodynamic support during the procedure,\n                  AND\n\n               2. the heart team has determined that the patient is not an optimal surgical\n                  candidate, OR the patient elects not to undergo surgery\n\n          -  Written, signed, and dated informed consent\n\n        Exclusion Criteria:\n\n          -  Emergent PCI\n\n          -  ST elevation myocardial infarction within 7 days of procedure\n\n          -  Cardiac arrest within 7 days of procedure requiring CPR or defibrillation\n\n          -  Hemodynamic support with the HeartMate PHP post-PCI is anticipated\n\n          -  Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria\n             OR altered sensorium OR cardiac index <2.2 L/min/m2)\n\n          -  Mural thrombus in the left ventricle\n\n          -  History of  aortic valve replacement\n\n          -  Documented presence of aortic stenosis (orifice area of 1.5cm2 or less)\n\n          -  Moderate to severe aortic insufficiency (echocardiographic assessment of aortic\n             insufficiency graded as 2 or higher)\n\n          -  Severe peripheral vascular disease\n\n          -  Abnormalities of the aorta that would preclude surgery, including aneurysms and\n             significant tortuosity or calcifications\n\n          -  Planned use of rotablator or atherectomy during the procedure\n\n          -  Serum creatinine > 3.5mg/dL within 7 days of procedure\n\n          -  Liver dysfunction with elevation of liver enzymes and bilirubin levels to \u2265 3x ULN or\n             INR (Internationalized Normalized Ratio) \u22652\n\n          -  Uncorrectable abnormal coagulation parameters\n\n          -  Active systemic infection requiring treatment with antibiotics\n\n          -  Clinically relevant stroke or TIA within 3 months of procedure. Patients with\n             suspected stroke or TIA within 3 months of procedure must have documented absence of\n             neurological infarction\n\n          -  Uncontrollable allergy or intolerance to heparin, aspirin, clopidogrel, ionic and\n             nonionic contrast media, or any other potentially required anticoagulants or\n             antiplatelet therapy drugs\n\n          -  History of heparin induced thrombocytopenia\n\n          -  Patient is pregnant or planning to become pregnant during the study period\n\n          -  Participation in another clinical study of an investigational drug or device that has\n             not met its primary endpoint-"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156609", 
            "org_study_id": "PHPCEMark"
        }, 
        "intervention": {
            "arm_group_label": "Percutaneous coronary intervention", 
            "description": "The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,", 
            "intervention_name": "Percutaneous ventricular support with the HeartMate PHP", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HeartMate PHP", 
            "HeartMate PHP CE Mark", 
            "Percutaneous coronary intervention", 
            "PCI", 
            "Percutaneous ventricular assist"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "seanhile@hotmail.com", 
                    "last_name": "Sergio Higuera, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bucaramanga", 
                        "country": "Colombia"
                    }, 
                    "name": "Instituto del Corazon"
                }, 
                "investigator": [
                    {
                        "last_name": "Boris Vesga, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Hector Hernandez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Juan Granada, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.lenzen@erasmusmc.nl", 
                    "last_name": "M. J. Lenzen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3000 CA"
                    }, 
                    "name": "Erasmus Medical Center"
                }, 
                "investigator": {
                    "last_name": "Robert Jan M. van Geuns, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "adrian_ebner@yahoo.com", 
                    "last_name": "Adrian Ebner, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Asuncion", 
                        "country": "Paraguay"
                    }, 
                    "name": "Sanatorio Italiano"
                }, 
                "investigator": {
                    "last_name": "Adrian Ebner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sdworowy@wp.pl", 
                    "last_name": "Sebastian Dworowy, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Katowice", 
                        "country": "Poland", 
                        "zip": "40-635"
                    }, 
                    "name": "Samodzielny Publiczny Szpital (The Prof. Leszka Gieca Upper-Silesian Medical Centre)"
                }, 
                "investigator": {
                    "last_name": "Andrzej Ochala, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "wgrzegorzak@su.krakow.pl", 
                    "last_name": "Wioletta Grzegorzak"
                }, 
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-202"
                    }, 
                    "name": "University Hospital in Krakow (John Paul II)"
                }, 
                "investigator": {
                    "last_name": "Krzysztof Zmudka, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "witkowski@hbz.pl", 
                    "last_name": "Adam Witkowski, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "04-628"
                    }, 
                    "name": "The Cardinal Stefan Wyszynski Institute of Cardiology"
                }, 
                "investigator": [
                    {
                        "last_name": "Adam Witkowski, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jacek Rozanski, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.zembala@sccs.pl", 
                    "last_name": "Marian Zembala, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zabrze", 
                        "country": "Poland", 
                        "zip": "41-800"
                    }, 
                    "name": "Slaskie Centrum Chorob Serca w Zabrzu (Silesian Center for Heart Disease)"
                }, 
                "investigator": {
                    "last_name": "Marian Zembala, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Colombia", 
                "Netherlands", 
                "Paraguay", 
                "Poland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "HeartMate\u00ae PHP CE Mark Clinical Investigation Plan", 
        "overall_contact": {
            "email": "mmacedo@thoratec.com", 
            "last_name": "Mark Macedo, BSN", 
            "phone": "781-852-8332"
        }, 
        "overall_official": {
            "affiliation": "Jagiellonian University Medical College", 
            "last_name": "Dariusz Dudek, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Paraguay: El Comite` de Bioetica de la Superintendencia de Salud", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary Performance Endpoint:\nFreedom from hemodynamic compromise during PCI procedure defined as: Mean Arterial Pressure (MAP) not falling below 60mm Hg for more than 10 minutes during the PCI procedure and additional pressor medication is not required.\nPrimary Endpoint will be evaluated at:\nPost procedure or at hospital discharge (whichever is longer)\n30 days post procedure", 
                "measure": "Primary Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "Post procedure or at hospital discharge (whichever is longer), 30 days post procedure"
            }, 
            {
                "description": "Primary Safety Endpoint:\nComposite of Major Adverse Events (MAE):\ndevice-related cardiac death,\nnew Q wave myocardial infarction,\nsurgical intervention due to device complication or malfunction,\ndevice-related access site complication requiring intervention or device-related limb ischemia,\ncerebral vascular accident (CVA),\nnew or worsening aortic valve insufficiency,\nmajor bleeding complication (BARC 3 or >),\nsevere hypotension\nPrimary Endpoint will be evaluated at:\nPost procedure or at hospital discharge (whichever is longer)\n30 days post procedure", 
                "measure": "Composite of Major Adverse Events (MAE)", 
                "safety_issue": "Yes", 
                "time_frame": "Post procedure or at hospital discharge (whichever is longer), 30 days post procedure"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy of hemodynamic support as measured by:\nMaximal decrease in cardiac power output (CPO) from baseline\nChanges in central venous pressure from baseline (CVP)\nChanges in pulmonary artery pressure from baseline (PAP)\nChanges in pulmonary capillary wedge pressure from baseline (PCWP)\nChanges in cardiac output from baseline (CO)\nChanges in cardiac index from baseline (CI)", 
                "measure": "Secondary Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "Post procedure or at hospital discharge (whichever is longer), 30 days post procedure"
            }, 
            {
                "description": "Individual components of the major adverse event composites", 
                "measure": "Major Adverse Event Composites", 
                "safety_issue": "Yes", 
                "time_frame": "Post procedure or at hospital discharge (whichever is longer), 30 days post procedure"
            }
        ], 
        "source": "Thoratec Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Thoratec Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}